Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 10/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5887244 | 0.91 | MAPK14 (0.44) | PDE4BTTKMAPK8THRBMCHR1 | |
| SCHEMBL5887013 | 0.90 | TTK (0.40) | PDE4BTTKMAPK8THRBMAPT | |
| SCHEMBL5887588 | 0.87 | SMN1; SMN2 (0.42) | PDE4BTTKMAPK8THRBMAPT | |
| SCHEMBL5887451 | 0.86 | MAPK8 (0.42) | PDE4BTTKMAPK8THRBMAPT | |
| SCHEMBL5886936 | 0.86 | MAOB (0.39) | MAPK8MAPT | |
| SCHEMBL5887445 | 0.85 | KMT2A (0.38) | PDE4BTTKMAPK8THRBMAPT | |
| SCHEMBL5886839 | 0.84 | MAPK14 (0.51) | — | |
| SCHEMBL5886732 | 0.82 | MAPK14 (0.48) | MAPT | |
| SCHEMBL5887029 | 0.82 | MAPK14 (0.48) | — | |
| SCHEMBL5887053 | 0.81 | MAPK14 (0.47) | MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | PDE4B 2197/4885SLC6A5 4851/4885PHGDH 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.